A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations
Publications
This is some text inside of a div block.
October 19, 2025
Related announcements
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress
